-

CincyTech Invests in Peerro, a Mobile-First Career Pathway Management System for Youth Employment, Employer Recruitment and Job Training

CINCINNATI--(BUSINESS WIRE)--CincyTech is pleased to announce an initial investment in Peerro, a career pathway management system enabling young people without college degrees to develop skills and land jobs that lead to advancement and financial independence. Peerro’s platform connects job seekers, educators and training programs with employers seeking quality hires to fill entry level positions.

Peerro is founded by Dr. Rachel Angel, who while beginning her professional career as a pharmacist, found the inspiration for Peerro in the hourly jobs that enabled her to work her way through six years of university. The name of the company sourced from some of the young jobseekers her company serves, seeing the tool being like a “peer hero” as they navigate career options.

“Peerro is a mission-driven company with bottom line benefits,” said Angel. “While elevating earning potential and career opportunities for young people, our platform improves business outcomes by creating a pipeline of qualified candidates, and reducing employee turnover.”

Peerro’s intuitive, mobile-first platform enables students to find entry level jobs and job training programs in their community. The app shows job seekers a roadmap of the steps and qualifications required for a given position and allows them to schedule an interview directly. Peerro works with schools and job preparedness programs to ensure students emerge with skills that match open jobs. Employers who are registered on the platform receive access to a pool of educator-endorsed, pre-vetted candidates.

“Rachel Angel is a force of nature. She’s driven to simultaneously make a difference to non-degreed workers, while helping employers hire motivated, entry level team members. At CincyTech, we readily saw the large market opportunity and Peerro’s scalable business model,” said Stacey Browning, managing director at CincyTech. Terms of the investment are undisclosed.

Job seekers can download the Peerro app for free. Job training programs and employers can learn more and register by visiting https://peerro.com. Peerro is headquartered in Cincinnati, Ohio.

ABOUT PEERRO

Peerro is a career pathway management system that facilitates job training, employee recruitment and youth employment.

ABOUT CINCYTECH

One of the Midwest’s most active seed investors, CincyTech helps to transform undeniably better ideas and innovation into high performing digital and human health companies.

Contacts

Peg Rusconi, Director of Communications, CincyTech
prusconi@cincytechusa.com
617-910-6217

CincyTech


Release Summary
CincyTech invests in Peerro, a mobile-first career pathway management system for youth employment, employer recruitment and job training .
Release Versions

Contacts

Peg Rusconi, Director of Communications, CincyTech
prusconi@cincytechusa.com
617-910-6217

Social Media Profiles
More News From CincyTech

Ravee Optics Secures $6 Million Seed Round as the Need to Move More Data in Space Explodes

DAYTON, Ohio--(BUSINESS WIRE)--A surge in data from the internet and AI is driving demand to move more of it in space. While computing power continues to advance, the ability to move data between satellites has become a critical bottleneck. This is expected to grow as industry giants consider building data centers in space. Ravee today announced an oversubscribed $6 million funding round led by BIG Capital, a Vietnam-based investment firm with several successful space tech investments in its po...

CORRECTING and REPLACING Kurome Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for KME-0584 for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS)

CINCINNATI--(BUSINESS WIRE)--Headline of release should read: Acute Myeloid Leukemia (instead of Acute Myeloid Lymphoma). The updated release reads: KUROME THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR KME-0584 FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) AND HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS) Entering the clinic in the second half of 2024, KME-0584, an IRAK1/4/panFIt3 Inhibitor is a first in class investigational drug for relapsed/refractory...

Eyas™ Medical Imaging Brings State-of-the-Art MRI to NICUs, Revolutionizing Access for Fragile Newborns

CINCINNATI--(BUSINESS WIRE)--Eyas announces the first for research use only installation of the neonatal MRI system, the Ascent3T™, within the NICU at Cincinnati Children’s....
Back to Newsroom